Syndax Pharmaceuticals, Inc. Board of Directors

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Dr. Peter Ordentlich B.Sc., Ph.D.

Dr. Peter Ordentlich B.Sc., Ph.D.

Co-Founder & Chief Scientific Officer

Mr. Keith Alan Goldan CPA

Mr. Keith Alan Goldan CPA

CFO, Treasurer & Chief Accounting Officer

Dr. Ronald M. Evans Ph.D.

Dr. Ronald M. Evans Ph.D.

Co-Founder, Advisor and Chair of Scientific Advisory Board

Dr. Neil Gallagher M.D., Ph.D.

Dr. Neil Gallagher M.D., Ph.D.

President, Head of Research & Development

Mr. Kevin McManus

Mr. Kevin McManus

Chief People Officer

Mr. Luke J. Albrecht J.D.

Mr. Luke J. Albrecht J.D.

Senior VP, General Counsel & Secretary

Sharon Klahre

Sharon Klahre

Vice President of Investor Relations & Communications

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.